SCHEMBL202347

SCHEMBL202347

O=C(c1ccccc1-c1ccccc1)N(O)OC(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ TACR1 P25103 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ BCAT2 O15382 1/20 0.46
▸ CHRNB2 P17787 2/20 0.41
▸ CHRNB4 P30926 2/20 0.41
▸ CHRNA3 P32297 2/20 0.41
▸ CHRNA4 P43681 2/20 0.41
▸ HTT P42858 2/20 0.40
▸ HNF4A P41235 1/20 0.40
▸ SCN1A P35498 3/20 0.40
▸ SCN2A Q99250 3/20 0.40
▸ SCN3A Q9NY46 3/20 0.40
▸ TSHR P16473 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ ABCB1 P08183 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484726 0.77 MEN1 (0.61) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
SCHEMBL201211 0.76 CES1 (0.45) SMN1; SMN2ALDH1A1TSHRPOLB
SCHEMBL27636022 0.73 BCAT2 (0.52) MEN1KMT2ASMN1; SMN2TACR1BCAT2
SCHEMBL28815916 0.72 BCAT2 (0.54) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
SCHEMBL6677412 0.71 MEN1 (1.00) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
SCHEMBL30463435 0.71 MEN1 (1.00) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
SCHEMBL307520 0.71 BCAT2 (0.57) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
Trifluoroacetic Acid SCHEMBL16720000 0.69 HNF4A (0.56) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
Hydrochloric Acid SCHEMBL20578422 0.69 MEN1 (0.96) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1
SCHEMBL29035974 0.69 BCAT2 (0.55) MEN1KMT2ASMN1; SMN2TACR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 — — US disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 — — US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 — — US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 — — EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 — — EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 MEN1 1037/4885KMT2A 380/4885SMN1; SMN2 3366/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MEN1 678/4885KMT2A 1011/4885SMN1; SMN2 1208/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 MEN1 1027/4885KMT2A 415/4885SMN1; SMN2 2959/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MEN1 678/4885KMT2A 1011/4885SMN1; SMN2 1208/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MEN1 678/4885KMT2A 1011/4885SMN1; SMN2 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback